Comparison of In vitro Nanoparticles Uptake in Various Cell Lines and In vivo Pulmonary Cellular Transport in Intratracheally Dosed Rat Model

In present study, the potential drug delivery of nanoformulations was validated via the comparison of cellular uptake of nanoparticles in various cell lines and in vivo pulmonary cellular uptake in intratracheally (IT) dosed rat model. Nanoparticles were prepared by a bench scale wet milling device and incubated with a series of cell lines, including Caco-2, RAW, MDCK and MDCK transfected MDR1 cells. IT dosed rats were examined for the pulmonary cellular uptake of nanoparticles. The processes of nanoparticle preparation did not alter the crystalline state of the material. The uptake of nanoparticles was observed most extensively in RAW cells and the least in Caco-2 cells. Efflux transporter P-gp did not prevent cell from nanoparticles uptake. The cellular uptake of nanoparticles was also confirmed in bronchoalveolar lavage (BAL) fluid cells and in bronchiolar epithelial cells, type II alveolar epithelial cells in the intratracheally administrated rats. The nanoparticles uptake in MDCK, RAW cells and in vivo lung epithelial cells indicated the potential applications of nanoformulation for poorly soluble compounds. The observed limited direct uptake of nanoparticles in Caco-2 cells suggests that the improvement in oral bioavailability by particle size reduction is via increased dissolution rate rather than direct uptake.

[1]  Patrick J. Sinko,et al.  Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells , 1998, Pharmaceutical Research.

[2]  I. Forgacs GASTROENTEROLOGY , 1988, The Lancet.

[3]  M. Aprahamian,et al.  Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine , 1987, Biology of the cell.

[4]  Cesario Z. Cerna,et al.  Effect of Nanonization on Absorption of 301029: Ex Vivo and In Vivo Pharmacokinetic Correlations Determined by Liquid Chromatography/Mass Spectrometry , 2002, Pharmaceutical Research.

[5]  Albert H. L. Chow,et al.  Particle Engineering for Pulmonary Drug Delivery , 2007, Pharmaceutical Research.

[6]  M. Odomi,et al.  Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[7]  D. Postma,et al.  Multidrug resistance related molecules in human and murine lung. , 2002, Journal of clinical pathology.

[8]  马建新,et al.  用FEV6.0代替FVC诊断气道阻塞和肺功能受限[英]/Swanney MP…∥Am J Respir Crit Care Med. , 2002 .

[9]  Patric Stenberg,et al.  Transport of Lipophilic Drug Molecules in a New Mucus-Secreting Cell Culture Model Based on HT29-MTX Cells , 2001, Pharmaceutical Research.

[10]  N Hussain,et al.  Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. , 2001, Advanced drug delivery reviews.

[11]  H. Melhus,et al.  Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. , 2001, The Journal of pharmacology and experimental therapeutics.

[12]  J. Tolan,et al.  MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.

[13]  B. Hirst,et al.  Exploiting M cells for drug and vaccine delivery. , 2001, Advanced drug delivery reviews.

[14]  G. Russell-Jones,et al.  Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. , 1999, International journal of pharmaceutics.

[15]  M. Gottesman,et al.  Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. , 2006, Molecular pharmaceutics.

[16]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Yang Pc,et al.  (Am. J. Respir. Cell Mol. Biol., 32:540-547)Autocrine and Paracrine Regulation of IL-8 Expression in Lung Cancer Cells , 2005 .

[18]  K. Audus,et al.  Contribution of efflux pump activity to the delivery of pulmonary therapeutics. , 2002, Current drug metabolism.

[19]  I. Hidalgo Cultured intestinal epithelial cell models. , 1996, Pharmaceutical biotechnology.

[20]  Alexander T. Florence,et al.  Enhanced Oral Uptake of Tomato Lectin-Conjugated Nanoparticles in the Rat , 1997, Pharmaceutical Research.

[21]  A. Florence,et al.  Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency , 1990, The Journal of pharmacy and pharmacology.

[22]  Minjie Sun,et al.  Chitosan surface-modified hydroxycamptothecin loaded nanoparticles with enhanced transport across Caco-2 cell monolayer. , 2006, Journal of nanoscience and nanotechnology.

[23]  J. P. Ebel A Method for Quantifying Particle Absorption from the Small Intestine of the Mouse , 1990, Pharmaceutical Research.

[24]  K. Carr,et al.  Factors influencing intestinal microparticle uptake in vivo. , 2007, International journal of pharmaceutics.

[25]  R. Gurny,et al.  pH-Sensitive Nanoparticles: An Effective Means to Improve the Oral Delivery of HIV-1 Protease Inhibitors in Dogs , 1996, Pharmaceutical Research.

[26]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[27]  G. Russell-Jones,et al.  Lectin-mediated transport of nanoparticles across Caco-2 and OK cells. , 1999, International journal of pharmaceutics.

[28]  B. Lehnert,et al.  Alveolar macrophage-particle relationships during lung clearance. , 1989, American journal of respiratory cell and molecular biology.

[29]  M F Hoylaerts,et al.  Passage of intratracheally instilled ultrafine particles from the lung into the systemic circulation in hamster. , 2001, American journal of respiratory and critical care medicine.

[30]  S. Baumgartner,et al.  Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. , 2006, International journal of pharmaceutics.

[31]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[32]  Wolfgang Kreyling,et al.  Ultrafine Particles Cross Cellular Membranes by Nonphagocytic Mechanisms in Lungs and in Cultured Cells , 2005, Environmental health perspectives.

[33]  D. Cremaschi,et al.  Identification of particular epithelial areas and cells that transport polypeptide-coated nanoparticles in the nasal respiratory mucosa of the rabbit. , 1999, Biochimica et biophysica acta.

[34]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[35]  L. Benet,et al.  Comparison of Bidirectional Cephalexin Transport Across MDCK and Caco-2 Cell Monolayers: Interactions with Peptide Transporters , 2004, Pharmaceutical Research.

[36]  J. Kreuter Drug targeting with nanoparticles , 1994, European Journal of Drug Metabolism and Pharmacokinetics.

[37]  Gordon L. Amidon,et al.  The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent , 1997, Pharmaceutical Research.

[38]  Thomas J. Raub,et al.  In vitro models of the blood-brain barrier. , 1998, Alternatives to laboratory animals : ATLA.

[39]  Min Huang,et al.  Uptake of FITC-Chitosan Nanoparticles by A549 Cells , 2002, Pharmaceutical Research.

[40]  Gordon L. Amidon,et al.  Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size , 1996, Pharmaceutical Research.

[41]  B. Lehnert,et al.  Correlation Between Particle Size, in Vivo Particle Persistence, and Lung Injury , 1994 .

[42]  W G Kreyling,et al.  Distribution Pattern of Inhaled Ultrafine Gold Particles in the Rat Lung , 2006, Inhalation toxicology.